Literature DB >> 22578059

The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology.

Valéry Lavergne1, Thomas D Nolin, Robert S Hoffman, Darren Roberts, Sophie Gosselin, David S Goldfarb, Jan T Kielstein, Robert Mactier, Robert Maclaren, James B Mowry, Timothy E Bunchman, David Juurlink, Bruno Megarbane, Kurt Anseeuw, James F Winchester, Paul I Dargan, Kathleen D Liu, Lotte C Hoegberg, Yi Li, Diane P Calello, Emmanuel A Burdmann, Christopher Yates, Martin Laliberté, Brian Scott Decker, Carlos Augusto Mello-Da-Silva, Eric Lavonas, Marc Ghannoum.   

Abstract

Extracorporeal treatments (ECTRs), such as hemodialysis and hemoperfusion, are used in poisoning despite a lack of controlled human trials demonstrating efficacy. To provide uniform recommendations, the EXTRIP group was formed as an international collaboration among recognized experts from nephrology, clinical toxicology, critical care, or pharmacology and supported by over 30 professional societies. For every poison, the clinical benefit of ECTR is weighed against associated complications, alternative therapies, and costs. Rigorous methodology, using the AGREE instrument, was developed and ratified. Methods rely on evidence appraisal and, in the absence of robust studies, on a thorough and transparent process of consensus statements. Twenty-four poisons were chosen according to their frequency, available evidence, and relevance. A systematic literature search was performed in order to retrieve all original publications regardless of language. Data were extracted on a standardized instrument. Quality of the evidence was assessed by GRADE as: High = A, Moderate = B, Low = C, Very Low = D. For every poison, dialyzability was assessed and clinical effect of ECTR summarized. All pertinent documents were submitted to the workgroup with a list of statements for vote (general statement, indications, timing, ECTR choice). A modified Delphi method with two voting rounds was used, between which deliberation was required. Each statement was voted on a Likert scale (1-9) to establish the strength of recommendation. This approach will permit the production of the first important practice guidelines on this topic.

Entities:  

Mesh:

Year:  2012        PMID: 22578059     DOI: 10.3109/15563650.2012.683436

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  19 in total

Review 1.  Extracorporeal Removal of Poisons and Toxins.

Authors:  Joshua David King; Moritz H Kern; Bernard G Jaar
Journal:  Clin J Am Soc Nephrol       Date:  2019-08-22       Impact factor: 8.237

Review 2.  Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Brian S Decker; David S Goldfarb; Paul I Dargan; Marjorie Friesen; Sophie Gosselin; Robert S Hoffman; Valéry Lavergne; Thomas D Nolin; Marc Ghannoum
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-12       Impact factor: 8.237

3.  Pediatric intradialytic hypotension: recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) Workgroup.

Authors:  Rupesh Raina; Stephanie Lam; Hershita Raheja; Vinod Krishnappa; Daljit Hothi; Andrew Davenport; Deepa Chand; Gaurav Kapur; Franz Schaefer; Sidharth Kumar Sethi; Mignon McCulloch; Arvind Bagga; Timothy Bunchman; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2019-02-08       Impact factor: 3.714

4.  Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus Statement.

Authors:  Brian H Eisner; David S Goldfarb; Michelle A Baum; Craig B Langman; Gary C Curhan; Glenn M Preminger; John C Lieske; Gyan Pareek; Kay Thomas; Anna L Zisman; Dimitri Papagiannopoulos; Roger L Sur
Journal:  J Endourol       Date:  2020-04-06       Impact factor: 2.942

5.  Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative.

Authors:  Thomas D Nolin; George R Aronoff; William H Fissell; Lokesh Jain; Rajnikanth Madabushi; Kellie Reynolds; Lei Zhang; Shiew Mei Huang; Rajnish Mehrotra; Michael F Flessner; John K Leypoldt; Jennifer W Witcher; Issam Zineh; Patrick Archdeacon; Prabir Roy-Chaudhury; Stuart L Goldstein
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-04       Impact factor: 8.237

Review 6.  Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb Therapy.

Authors:  Joerg Scheier; Peter J Nelson; Antoine Schneider; Sébastien Colombier; Detlef Kindgen-Milles; Efthymios N Deliargyris; Thomas D Nolin
Journal:  Crit Care Explor       Date:  2022-05-09

7.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

8.  Assessment of Extracorporeal Treatments in Poisoning criteria for the decision of extracorporeal toxin removal in lithium poisoning.

Authors:  Dominique Vodovar; Sébastien Beaune; Jérôme Langrand; Eric Vicaut; Laurence Labat; Bruno Mégarbane
Journal:  Br J Clin Pharmacol       Date:  2019-08-30       Impact factor: 4.335

9.  Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.

Authors:  Tripti Singh; Thin Thin Maw; Brian L Henry; Núria M Pastor-Soler; Mark L Unruh; Kenneth R Hallows; Thomas D Nolin
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

10.  Tissue concentration of paraquat on day 32 after intoxication and failed bridge to transplantation by extracorporeal membrane oxygenation therapy.

Authors:  Anna Bertram; Sascha Sebastian Haenel; Johannes Hadem; Marius M Hoeper; Jens Gottlieb; Gregor Warnecke; Stanislav Kaschinski; Carsten Hafer; W Nikolaus Kühn-Velten; Detlef Günther; Jan T Kielstein
Journal:  BMC Pharmacol Toxicol       Date:  2013-09-06       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.